CTOR
Citius Oncology, Inc.NASDAQHealthcare$0.70+8.47%ClosedMarket Cap: $62.1M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.05
P/S
15.73
EV/EBITDA
-2.69
DCF Value
$0.11
FCF Yield
-20.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.0%
Operating Margin
-567.4%
Net Margin
-599.3%
ROE
-55.2%
ROA
-21.5%
ROIC
-34.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.9M | $-5.5M | $-0.06 |
| Q4 2025 | $0.00 | $-5.0M | $-0.06 |
| FY 2025 | $0.00 | $-24.8M | $-0.34 |
| Q3 2025 | $0.00 | $-5.4M | $-0.08 |
Analyst Ratings
View AllMaxim GroupBuy
2025-09-23Maxim GroupHold
2025-05-23Trading Activity
Insider Trades
View AllHOLUBIAK MYRON Zdirector, officer: Secretary
SellTue Sep 23
HOLUBIAK MYRON Zdirector, officer: Secretary
SellTue Sep 23
Smith Robert Josephdirector
SellTue Sep 23
Mazur Leonard Ldirector, officer: Chief Executive Officer
SellTue Sep 23
Webb Caroldirector
SellTue Sep 23
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
3.43
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.